The possibilities of atherosclerosis prevention in type 2 diabetes mellitus

Czech version

Authors: I. Tkáč
Authors‘ workplace: IV. interná klinika Lekárskej fakulty UPJŠ a FN L. Pasteura, Košice, Slovenská republika, prednosta prof. MUDr. Ivan Tkáč, Ph. D.
Published in: Vnitř Lék 2005; 51(6): 718-724
Category: Reviews

Overview

The prevention of atherosclerosis in type 2 diabetes should start a long time before the diagnosis of diabetes is done by early screening of the high risk individuals based on their family history or on the presence of obesity, hypertension, dyslipidemia, impaired fasting glucose or microalbuminuria. Early lifestyle and drug interventions in such subjects are able to delay both the development of diabetes and atherosclerosis. After making the diagnosis of diabetes, it is necessary to begin or to continue with multifactorial intervention (reviewed in the table), which will eventually lead to reduction of incidence of macrovascular diseases in diabetes at least by one half.

Key words:
type 2 diabetes mellitus – atherosclerosis – macrovascular complications – risk factors – insulin resistance

Sources

1. Howard BV, Robbins DC, Sievers ML et al. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL. The Strong Heart Study. Arterioscler Thromb Vasc Biol 2000; 20: 830–835.

2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837–853.

3. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. Br Med J 1997; 314: 1512–1515.

4. Haffner SM, Alexander CM, Cook TJ et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Stduy. Arch Intern Med 1999; 159: 2661–2667.

5. Sacks FM, Tonkin AM, Craven T et al. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 2002; 105: 1424–1428.

6. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Heart Protection Study Collaborative Group. Lancet 2002; 360: 7–22.

7. Rubins HB, Robins SJ, Collins D et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs highdensity lipoprotein intervention trial (VA–HIT). Arch Intern Med 2002; 162: 2597–2604.

8. Rašlová K, Filipová S, Mikeš Z et al. Odporúčania pre optimálnu diagnostiku a liečbu dyslipoproteinémií u dospelých: „Lipidový konsenzus – 2“. Interná Med 2003; 3: 10–18.

9. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. Br Med J 1998; 317: 703–713.

10. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755–1762.

11. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854–865.

12. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355: 253–259.

13. Collins R, Baigent C, Sandercock P et al. Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials. Antiplatelet Trialists’ Collaboration. Br Med J 1994; 309: 1215–1217.

14. Ponťuch P. Preventívne stratégie při diabetickej nefropatii. Interná Med 2002; 2: 370–373.

15. Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383–393.